These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39289642)

  • 1. Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.
    Kobayashi T; Nishimura M; Hosonaga M; Kizawa R; Kawai S; Aoyama Y; Ozaki Y; Fukada I; Hara F; Takano T; Ueno T
    BMC Cancer; 2024 Sep; 24(1):1156. PubMed ID: 39289642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.
    Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S
    EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
    Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
    Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
    Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
    Seki H; Sakurai T; Maeda Y; Oki N; Aoyama M; Yamaguchi R; Tokuda T; Kaburagi T; Okumura T; Karahashi T; Nakajima K; Higeta K; Shimizu K
    In Vivo; 2019; 33(6):2037-2044. PubMed ID: 31662535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
    Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
    Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
    Sun J; Zhong X; Ma J; Sun W; Han HS; Soliman HH; Loftus LS; Costa RLB; Armaghani AJ; Soyano-Muller AE; Czerniecki BJ; Lee MC; Kiluk JV; Khakpour N; Hoover SJ; Laronga C; Khong HT
    Cancer Med; 2021 Nov; 10(21):7665-7672. PubMed ID: 34590788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
    Porte B; Carton M; Lerebours F; Brain E; Loirat D; Haroun L; Bellesoeur A; Bach Hamba S; Kirova Y; Cottu P
    Breast; 2020 Dec; 54():303-310. PubMed ID: 33242757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
    Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
    Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
    Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
    Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
    Malorni L; Curigliano G; Minisini AM; Cinieri S; Tondini CA; D'Hollander K; Arpino G; Bernardo A; Martignetti A; Criscitiello C; Puglisi F; Pestrin M; Sanna G; Moretti E; Risi E; Biagioni C; McCartney A; Boni L; Buyse M; Migliaccio I; Biganzoli L; Di Leo A
    Ann Oncol; 2018 Aug; 29(8):1748-1754. PubMed ID: 29893790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
    Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
    J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
    Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
    Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.